Regorafenib approved for advanced bowel cancer
The TGA has approved a new treatment for advanced bowel cancer, regorafenib (Stivarga), that may prolong survival in patients who have become resistant to other therapies.
Regorafenib is the first oral multikinase inhibitor approved for bowel cancer in Australia, according to manufacturer Bayer.
The TGA approval was based on a clinical showing regorafenib increased survival by an average of 1.4 months in patients with advanced colorectal cancer compared to placebo in patients previously treated with chemotherapy and other therapies such as anti-VEGF therapy and anti-EGFR therapy.
In the US, where it is